Omnicell appoints Nnamdi Njoku as EVP and COO, effective Oct 7

OMNICELL, INC.

Nnamdi Njoku named EVP and Chief Operating Officer; role reports to CEO Randall Lipps.
Njoku previously President at Zimmer Biomet and SVP/President at Medtronic; ~25 years experience.
Initial base salary $645,000; eligible for Q4 special bonus of $161,250 and one-time equity award of ~$2.25M RSUs.
2025 equity awards include RSUs of ~$1.5M and PSUs of ~$1.5M based on relative TSR over one year.
Eligible for Executive Bonus Plan with target cash bonus of 100% of base salary and severance benefits.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Nnamdi Njoku

Executive Vice President and Chief Operating Officer

OMCL · OMNICELL, INC.

Effective: 2024-10-07
Filed: September 25, 2024, 7:59 PM ET

On September 25, 2024, Omnicell, Inc. (“Omnicell” or the “Company”) announced that Nnamdi Njoku, age 48, has been appointed Executive Vice President and Chief Operating Officer of the Company, effective October 7, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Nnamdi Njoku was appointed as Executive Vice President and Chief Operating Officer at OMNICELL, INC..

Action: appointed
Role: Executive Vice President and Chief Operating Officer

Exact text from the filing

On September 25, 2024, Omnicell, Inc. (“Omnicell” or the “Company”) announced that Nnamdi Njoku, age 48, has been appointed Executive Vice President and Chief Operating Officer of the Company, effective October 7, 2024.

View on SEC.gov

OMNICELL, INC. filing history →

Source: SEC EDGAR

accession 0001104659-24-102781

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.